IP Library Granted Patent US 9,457,041
Granted Patent B2
US 9,457,041 · App. 14/744,705 · Granted Oct 4, 2016

Controlled release nanoparticles and methods of use

Inventors: Prajakta S. Kulkarni (Fargo, ND); Manas K. Haldar (Fargo, ND); Sanku Mallik (West Fargo, ND); D. K. Srivastava (Reilies Acres, ND)
Assignee: NDSU Research Foundation
A61K31/7068A61K9/0019A61K9/1271A61K49/0093
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,457,041
App. No.
14/744,705
Granted
Oct 4, 2016
Kind
B2
Abstract

Provided herein are nanoparticles that include a lipid layer and a compartment surrounded by the lipid layer. The lipid layer may include a lipid and a lipoprotein. The lipid may include a POPE lipid covalently attached to a hydrophilic polymer by a disulfide bond. The lipoprotein may include a trigger protein. The concentration of the first lipid may be between 1 mol % and 30 mol %. The disulfide bond of the first lipid is stable under conditions that include 10% human serum and is broken under conditions that include 50 micromolar glutathione. The hydrophilic polymer may include a PEG molecule. The trigger protein may include an amino acid repeat region, such as (GPX)n. The trigger protein may include a peptide bond that is cleaved by a gelatinase (e.g., gelatinase-B protease), or a member of the ADAM family of proteases (e.g., ADAM10 protease). Also provided are methods of using the nanoparticles.

Claims (27)

1. A nanoparticle comprising a lipid layer and a compartment surrounded by the lipid layer,

wherein the lipid layer comprises (i) a first lipid, the first lipid comprising a POPE lipid covalently attached to a hydrophilic polymer by a disulfide bond, and (ii) a lipoprotein, the lipoprotein comprising a trigger protein,

wherein the concentration of the first lipid is between 1 mole percent (mol %) and 30 mol %, and

wherein the disulfide bond of the first lipid is stable under conditions comprising 10% human serum and is broken under conditions comprising 50 micromolar glutathione.

2. The nanoparticle of claim 1 wherein the trigger protein comprises an amino acid repeat region.

3. The nanoparticle of claim 2 wherein the amino acid repeat region comprises (GPX)n, wherein X is 4-hydroxyproline or proline, and n is at least 3.

4. The nanoparticle of claim 2 wherein the trigger protein comprises a peptide bond that is cleaved by a gelatinase or a member of the ADAM family of proteases.

5. The nanoparticle of claim 4 wherein the gelatinase is gelatinase-B protease.

6. The nanoparticle of claim 4 wherein the member of the ADAM family of proteases is ADAM10 protease.

7. The nanoparticle of claim 6 wherein the trigger protein comprises an amino acid sequence GPL GLA RKG (GPO) 4 (SEQ ID NO:15).

8. The nanoparticle of claim 1 wherein the compartment comprises a compound.

9. The nanoparticle of claim 8 wherein the compound is an inhibitor of a gelatinase or a member of the ADAM family of proteases.

10. The nanoparticle of claim 8 wherein the compound is a therapeutic agent.

11. The nanoparticle of claim 8 wherein the compound is a non-therapeutic agent.

12. A nanoparticle comprising a lipid layer and a compartment surrounded by the lipid layer,

wherein the lipid layer comprises (i) a first lipid, the first lipid covalently attached to a hydrophilic polymer by a disulfide bond, and (ii) a lipoprotein, the lipoprotein comprising a trigger protein, wherein the trigger protein comprises a peptide bond that is cleaved by a member of the ADAM family of proteases,

wherein the concentration of the first lipid is between 1 mole percent (mol %) and 30 mol %, and

wherein the disulfide bond of the first lipid is stable under conditions comprising 10% human serum and is broken under conditions comprising 50 micromolar glutathione.

13. The nanoparticle of claim 12 wherein the member of the ADAM family of proteases is ADAM10 protease.

14. The nanoparticle of claim 13 wherein the trigger protein comprises an amino acid sequence GPL GLA RKG (GPO) 4 (SEQ ID NO:15).

15. The nanoparticle of claim 12 wherein the compartment comprises a compound.

16. The nanoparticle of claim 15 wherein the compound is an inhibitor of a member of the ADAM family of proteases.

17. The nanoparticle of claim 15 wherein the compound is a therapeutic agent.

18. The nanoparticle of claim 15 wherein the compound is a non-therapeutic agent.

19. A method for delivering a compound to an environment, the method comprising:

providing the nanoparticle of claim 1 , wherein the compartment comprises a compound;

exposing the nanoparticle to an environment comprising (i) a reducing agent at a concentration sufficient to break the disulfide bond of the first lipid, and (ii) an enzyme that cleaves a peptide bond of the trigger protein, wherein exposure of the nanoparticle to the environment results in release of the compound from the compartment.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2015
From: KULKARNI, PRAJAKTA S.; HALDAR, MANAS K.; MALLIK, SANKU; SRIVASTAVA, D. K.
To: NORTH DAKOTA STATE UNIVERSITY
Reel/Frame 036348/0070 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2015
From: NORTH DAKOTA STATE UNIVERSITY
To: NDSU RESEARCH FOUNDATION
Reel/Frame 036348/0193 →
CONFIRMATORY LICENSE Recorded Jul 1, 2015
From: NORTH DAKOTA STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036048/0961 →
Continuity (2)
Provisional Application 62015213 · Jun 20, 2014
Related Publication 20160000724A1 · Jan 7, 2016